Package Leaflet: Information for the User
Soludronate Weekly 70 mg Oral Solution
Alendronic Acid
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information:
Soludronate Weekly 70 mg Oral Solution will be referred to as Soludronate Weekly throughout this leaflet.
Soludronate Weekly belongs to a group of non-hormonal medicines called bisphosphonates. Soludronate Weekly is used to:
Your doctor has prescribed Soludronate Weekly to treat your osteoporosis and reduce the risk of spinal and hip fractures.
What is osteoporosis?
Osteoporosis is a thinning and weakening of the bones. It is common in women after menopause. During menopause, the ovaries stop producing the female hormone, estrogen, which helps maintain the health of a woman's skeleton. As a result, bone loss occurs and the bones weaken. The earlier a woman reaches menopause, the greater the risk of osteoporosis.
At first, osteoporosis does not usually cause symptoms. However, if left untreated, it can cause bones to fracture. Although these fractures are usually painful, those that occur in the spine may go unnoticed until a loss of height is observed. Bones can break during normal daily activity, such as lifting objects, or due to minor trauma that would not normally break a healthy bone. Fractures usually occur in the head, spine, or wrist and can cause not only pain but also significant problems, such as a hunched posture (kyphosis) and loss of mobility.
How can osteoporosis be treated?
Osteoporosis can be treated, and it's never too late to start treatment. Alendronic acid not only prevents bone loss but also actually helps rebuild bone after it has been lost and reduces the risk of bone fractures in the spine and hip.
In addition to your treatment with Soludronate Weekly, your doctor may recommend lifestyle changes to improve your condition, such as:
Quitting smoking:Smoking appears to increase the rate of bone loss, thereby increasing the risk of fractures.
Exercise:Like muscles, bones need to be exercised to stay strong and healthy. Consult your doctor before starting any exercise program.
Following a balanced diet:Your doctor may advise you on your diet or the need to take dietary supplements (especially calcium and vitamin D).
Do not take Soludronate Weekly
If you think any of these apply to you, do not take the solution. Talk to your doctor first and follow their advice.
Warnings and precautions
Talk to your doctor or pharmacist before starting Soludronate Weekly if:
You may be advised to have a dental check-up before starting treatment with Soludronate Weekly. During treatment, adequate preventive dental care is necessary, as recommended by your dentist. You should contact your doctor or dentist if you experience any problems with your mouth or teeth, such as tooth loss, pain, or swelling.
Irritation, inflammation, or ulcers of the esophagus (the tube that connects the mouth to the stomach) can occur, often with symptoms of chest pain, heartburn, or difficulty or pain when swallowing, especially if patients lie down after taking Soludronate Weekly. These side effects can worsen if patients continue taking Soludronate Weekly after experiencing these symptoms.
Children and adolescents
Soludronate Weekly should not be given to children or adolescents under 18 years of age due to insufficient data on safety and efficacy.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
It is likely that food and drinks (such as mineral water) will reduce the effectiveness of Soludronate Weekly if taken at the same time. Therefore, it is important that you follow the instructions in section 3. How to take Soludronate Weekly.
The use of Soludronate Weekly is only intended for postmenopausal women.
Do not take Soludronate Weekly if you are pregnant or think you may be pregnant, or are breastfeeding.
Ask your doctor or pharmacist for advice before taking any medicine.
Side effects (such as blurred vision, dizziness, and severe bone, muscle, or joint pain) have been reported with alendronic acid that could affect your ability to drive or use machines. Individual responses to alendronic acid may vary (see section 4. Possible side effects).
This medicine contains orange yellow S (E110) and methyl parahydroxybenzoate and propyl parahydroxybenzoate (E218, E216), which may cause allergic reactions (possibly delayed). Allergy is more frequent if you are allergic to aspirin. Ask your doctor or pharmacist if you have any doubts.
This medicine contains a volume of 0.15% ethanol (alcohol), i.e., up to 115 mg per dose, which is equivalent to 3 ml of beer or 1.3 ml of wine per dose, so it may be harmful to patients with alcoholism. It is also necessary to take this into account in high-risk groups, such as patients with liver disease or epilepsy.
Follow exactly the instructions for administration of Soludronate Weekly given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
The recommended dosage is a single dose of 70 mg (100 ml) once a week.
Follow these instructions carefully to ensure you benefit from Soludronate Weekly.
Choose the day of the week that best suits your routine. Each week, take Soludronate Weekly on the day you have chosen.
If you take more Soludronate Weekly than you should
If you take too much solution by mistake, drink a full glass of milk.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested. Do not induce vomiting or lie down.
If you forget to take Soludronate Weekly
If you forget a dose, take the dose the next morning after you remember. Do not take two doses on the same day. Take a dose once a week, as originally scheduled on your chosen day.
If you stop taking Soludronate Weekly
It is important that you continue taking Soludronate Weekly for as long as your doctor prescribes it. Soludronate Weekly can only treat your osteoporosis if you continue taking it.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediatelyif you notice any of the following side effects, as they can be serious and may require urgent medical treatment:
Common:may affect up to 1 in 10 people
Rare:may affect up to 1 in 1,000 people
Other side effects:
Very common:may affect more than 1 in 10 people
Very rare:may affect up to 1 in 10,000 people
Tell your doctor or pharmacist about these symptoms or any other unusual symptoms. It is useful to make a note of what you experienced, when it started, and how long it lasted.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle. The expiry date is the last day of the month shown.
Store below 25°C.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Active ingredient:
The active ingredient is alendronate sodium trihydrate. Each 100 ml of solution contains 70 mg of alendronic acid as alendronate sodium trihydrate.
Other ingredients are:
Xanthan gum (E415), sodium cyclamate (E952), sucralose (E955), orange yellow S (E110), methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), orange flavor with ethanol and butylhydroxyanisole (E320), and purified water.
Soludronate Weekly is an orange-colored solution. It is available in transparent polyethylene terephthalate (PET) bottles with a safety seal and a low-density polyethylene coating in pack sizes of 1, 2, 4, and 12 bottles. Each bottle contains 100 ml of solution and is for single use only.
Only some pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Laboratorios Rubió, S.A.
C/ Industria, 29. Pol. Ind. Comte de Sert
08755 Castellbisbal (Barcelona)
Spain
Manufacturer:
PINEWOOD LABORATORIES LTD
Ballymacarbry
Clonmel
County Tipperary
Ireland
or
Chanelle Medical
Dublin Road
Loughrea
Co. Galway
Ireland
This medicinal product is authorized in the EEA Member States under the following names:
Bonasol: Austria, Belgium, Czech Republic, Denmark, Finland, France, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Portugal, Romania, Slovak Republic.
Alenat: Sweden
Alendron: Germany
Alendronic Acid Oral solution: United Kingdom
Soludronate: Spain
Date of the last revision of this leaflet:October 2021.
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of SOLUDRONATE SEMANAL 70 mg ORAL SOLUTION in October, 2025 is around 9.99 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.